Pharmaceuticals
The cannabis market: helping investors navigate the UK regulatory regime
25 June 2019 - Posted by: Matthew Townsend
Last year the global legal cannabis market was estimated to be worth USD12 billion but it is tipped to rise to over USD166 billion by 2025. Liberalisation of the legal framework for cannabis is a significant driver for this growth. Since 1 November 2018, the UK has joined the ranks of over 30 countries legalising › Read More
20 June 2019 - Posted by: Roberta Errico
For the second time, the Italian Ministry of Defence has launched an open tender for an urgent need of cannabis for therapeutic purposes by the Florence Pharmaceutical Chemical Plant. The estimated reference price of the tender is EUR 1,520,000 (net of VAT) for 400 kg, which represents an average of EUR 3.8 per gram. This › Read More
Medical cannabis in France: Latest state of play
12 June 2019 - Posted by: Eveline Van Keymeulen
Following the penultimate meeting of the specialised committee on cannabis (CSST) established by the French National Agency of Medicine and Health Products Safety (ANSM) (see our previous blog posts “French ANSM temporary scientific committee pursues activities on modalities of medical cannabis availability” and “French ANSM recommends medical use of cannabis under certain conditions“), the French Senate › Read More
11 June 2019 - Posted by: Sophie ten Bosch
At the latest meeting of EU agriculture ministers, and following a report by the Danish Council of Ethics, 14 EU member states, led by the Netherlands and Estonia, called for the European Commission to re-evaluate the EU’s stance on genetically modified organisms (GMOs), in particular those created by new plant breeding techniques. In a ruling › Read More
CJEU upholds withdrawal of orphan designation based on increased availability
10 June 2019 - Posted by: Jacqueline Bore
The EU’s General Court, whose jurisdiction includes the judicial review of decisions made by the EU institutions such as European Medicines Agency, has recently considered an interesting application in relation to a medicinal product that had been granted orphan designation on the little used basis that its significant benefit lay in its potential authorisation in › Read More